Related Experiment Videos
[Clinical experiences with a new topical steroid].
Zeitschrift Fur Hautkrankheiten
|January 1, 1975
Summary
Desoximetason (0.25%) demonstrated superior efficacy compared to Betamethasone-valerate (0.1%) in a randomized trial. Further open-label testing confirmed Desoximetason
Area of Science:
- Dermatology
- Clinical Pharmacology
- Pharmacotherapy
Background:
- Topical corticosteroids are mainstays in treating inflammatory skin conditions.
- Comparing the efficacy and tolerability of different corticosteroid formulations is crucial for optimizing treatment.
Purpose of the Study:
- To compare the efficacy and tolerability of Desoximetason (0.25%) versus Betamethasone-valerate (0.1%).
- To evaluate Desoximetason in a larger patient cohort under open-label conditions.
Main Methods:
- A randomized, double-blind, left-right comparative trial involving 44 patients.
- An open-label trial assessing Desoximetason in 280 patients.
Main Results:
- Desoximetason showed significantly better outcomes than Betamethasone-valerate across most observation periods.
- The double-blind trial excluded the 1-2 day observation period from this significant finding.
- The open-label trial indicated good efficacy and tolerability for Desoximetason.
Conclusions:
- Desoximetason (0.25%) appears to be a more effective topical corticosteroid than Betamethasone-valerate (0.1%).
- Desoximetason exhibits favorable efficacy and tolerability profiles, supporting its clinical use.